Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5928301 | 0.85 | MEN1 (0.51) | AAK1MEN1KMT2ANPC1PIN1 | |
| SCHEMBL1067741 | 0.84 | MEN1 (0.46) | AAK1MEN1KMT2ANPC1PIN1 | |
| SCHEMBL1067740 | 0.84 | MEN1 (0.46) | AAK1MEN1KMT2ANPC1PIN1 | |
| SCHEMBL14493754 | 0.82 | AAK1 (0.54) | AAK1MEN1KMT2ANPC1PIN1 | |
| SCHEMBL1688571 | 0.82 | AAK1 (0.57) | AAK1MEN1KMT2ANPC1PIN1 | |
| SCHEMBL1068082 | 0.81 | AAK1 (0.56) | AAK1MEN1KMT2ANPC1PIN1 | |
| SCHEMBL28269146 | 0.81 | AAK1 (0.53) | AAK1MEN1KMT2ANPC1PIN1 | |
| SCHEMBL28269226 | 0.81 | AAK1 (0.74) | AAK1MEN1KMT2ANPC1PIN1 | |
| SCHEMBL1883501 | 0.80 | AAK1 (0.52) | AAK1MEN1KMT2ANPC1PIN1 | |
| SCHEMBL13950541 | 0.79 | MEN1 (0.46) | AAK1MEN1KMT2ANPC1PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376469-A1 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| WO-2025111414-A1 | TRPM3-MODULATING BENZOFURAN DERIVATIVES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025111415-A1 | TRPM3-MODULATING INDOLIZINE DERIVATIVES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-05-30 | — | — | WO | disclosed |
| CN-119998280-A | Pyrazolo [1,5-a ] pyridine derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-119677717-A | Indolazine derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-03-21 | — | — | CN | disclosed |
| EP-4499636-A2 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| EP-4499608-A1 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230543-A1 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| CN-104640847-B | Novel Renin Inhibitors | 上海医药集团股份有限公司 | 2019-10-15 | — | — | CN | disclosed |
| EP-2933248-B1 | NOVEL RENIN INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2933248-A1 | NOVEL RENIN INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | AAK1 3259/4885MEN1 1507/4885KMT2A 1998/4885 |
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM5, TRPM4 | AAK1 848/4885MEN1 1479/4885KMT2A 3169/4885 |
| US-20250376469-A1 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM4, TRPM2 | AAK1 671/4885MEN1 1648/4885KMT2A 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.